FDA Approves First Muscle Targeting Therapy for Spinal Muscular Atrophy

The FDA has approved Isembyld, known generically as apitegromab, as an add on treatment for spinal muscular atrophy in patients age 2 and older who are already on an SMN2 targeted therapy, according to an FDA announcement. SMA is a rare genetic disease that damages motor neurons and causes progressive muscle wasting. Existing treatments correct the underlying SMN2 gene defect, but many patients with advanced disease still lose motor function. Isembyld works differently: it targets myostatin, a protein that normally restrains muscle growth, an approach related to the mechanism explored in research grade myostatin inhibitor compounds.

Approval rested on a 52 week randomized, double blind, placebo controlled trial of 188 participants ages 2 to 21 who could not walk or move independently. In the primary analysis group, ages 2 to 12, patients on the 10 mg per kg dose were more than twice as likely as placebo patients to show a clinically meaningful improvement in motor function, 34.2 percent versus 13.5 percent. The drug carries a warning for increased fracture risk, along with common side effects like respiratory infections and vomiting. This is an approved prescription medication for a diagnosed rare disease, not a research compound, and it has no bearing on the legal status of unapproved myostatin inhibiting peptides sold for laboratory use.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.